Zolucatetide (FOG-001)
Phase 1/2Desmoid tumors
Data readoutStock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| Zolucatetide (FOG-001) (Beta-Catenin Inhibitor) | Adamantinomatous Craniopharyngioma | Phase 1/2 | Jun 30, 2027 | — |
| Zolucatetide (FOG-001) | Familial adenomatous polyposis (FAP) | Phase 1/2 | Dec 31, 2026 | — |
| Zolucatetide (FOG-001) | Desmoid tumors | Phase 1/2 | Oct 23, 2026 | — |
Upcoming milestones
Desmoid tumors
Data readoutCompany profile
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Familial adenomatous polyposis (FAP)
Data readout